- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04115059
Dasatinib In Waldenström Macroglobulinemia
Dasatinib in Patients With Waldenström Macroglobulinemia (WM) Progressing on Ibrutinib
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This research study is a Pilot Study, which is the first time investigators are examining this drug in patients with Waldenström Macroglobulinemia who have progressed on ibrutinib.
Patients who fulfill eligibility criteria will be entered into the trial to receive Dasatinib
After the screening procedures confirm participation in the research study:
The participant will be given a study drug-dosing calendar for each treatment cycle. In this research study, the investigators are planning to give Dasatinib, which is a targeted therapy intended to treat cancer by binding to the target protein called BTK.
- BTK is believed to be an important target for treatment of patients with specific gene mutations. Some patients who have disease progression after taking ibrutinib have these gene mutations.
- Making treatment decisions based on genetic testing is investigational, and the FDA has not approved this genetic testing.
The U.S. Food and Drug Administration (FDA) has not approved Dasatinib for Waldenström Macroglobulinemia but it has been approved for other uses.
Dasatinib is produced by Bristol-Myers Squibb.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Jorge Castillo, MD
- Phone Number: (617) 632-4218
- Email: jorgej_castillo@dfci.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical exam, and laboratory assessments will be done within 30 days prior to Cycle 1 Day 1. Bone marrow biopsy & aspirate, and CT C/A/P will be done within 90 days prior to Cycle 1 Day 1.
- Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia
- Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory.
- Participants must have a BTKCys481 and/or PLCγ2 mutation. Genomic alterations must be confirmed via sequencing performed at NeoGenomics Laboratories
- At least one previous therapy, with ibrutinib as the most recent treatment. Participants may remain on ibrutinib therapy during screening. A 1 day washout before starting dasatinib is required.
- Documented disease progression on last regimen (ibrutinib) per the Sixth International Workshop on WM. One or more of the following:
- 25% increase in serum IgM level with at least 500 mg/dL absolute increase from nadir with re-confirmation
- Progression of clinically significant disease related symptoms
Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on WM [26]. One or more of the following:
- Constitutional symptoms
- Progressive or symptomatic lymphadenopathy or splenomegaly
- Hemoglobin <10 g/dL
- Platelet count <100 k/uL
- Symptomatic peripheral neuropathy
- Systemic amyloidosis
- Renal insufficiency
- Symptomatic cryoglobulinemia
- Age 18 years or older
- Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum serum IgM level of > 2 times the upper limit normal.
- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
- Women of childbearing potential: Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed.
- Men must agree to use a latex condom during sexual contact with a female of childbearing potential (FCBP) even if they have had a successful vasectomy.
Participants must have normal organ and marrow function as defined below:
- Absolute neutrophil count ≥500/ uL (Growth factor not permitted)
- Platelets ≥50,000/ uL (Platelet transfusion not permitted)
- Hemoglobin ≥ 7 g/dL (RBC transfusion permitted)
- Total bilirubin ≤ 2 mg/dL
- Potassium ≥ LLN
- Magnesium ≥ LLN
- AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal
- Estimated GFR ≥ 30 ml/min
- Able to swallow pills.
- Able to adhere to the study visit schedule and other protocol requirements.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study:
- Lactating or pregnant women.
- Participants who are receiving any other investigational agents.
- Prior therapy with BCR-ABL inhibitors.
- Known CNS lymphoma.
- Symptomatic hyperviscosity requiring urgent therapy.
- Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV).
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pleural or pericardial effusion, unstable angina pectoris, cardiac arrhythmia, QT Prolongation, or psychiatric illness/social situations that would limit compliance with study requirements.
- Prolonged QTc interval on pre-entry electrocardiogram (> 450 msec)
- History clinically significant ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes
- Known history of alcohol or drug abuse
- On any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.
- History of non-compliance to medical regimens.
- Treatment with strong CYP3A4/5 inhibitors or inducers
- Participants who are taking St. Johns Wort. Must discontinue at least 5 days before starting dasatinib.
- Treatment with H2 Antagonists and proton pump inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dasatinib
-- After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. Dasatinib: Oral Study Drug(s):
|
Oral, daily, dosing per protocol, once a day for cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With at Least One Treatment-Emergent Adverse Event
Time Frame: 2 years
|
Count of participants who experience a treatment-emergent adverse event
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate
Time Frame: 2 years
|
Percentage of patients with an Overall Response.
Overall Response Rate= Minor response (>25%-50% reduction in serum IgM from baseline) + Partial Response (>50-90% reduction in serum IgM from baseline) + Very Good Partial Response (>90% reduction in serum IgM from baseline) + Complete Response (resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, resolution of any adenopathy or splenomegaly).
|
2 years
|
Complete Response Rate
Time Frame: 2 years
|
Percentage of patients with Complete Response (CR).
Complete Response requires resolution of all symptoms, normalization of serum IgM with disappearance of IgM paraprotein, and resolution of any adenopathy or splenomegaly.
|
2 years
|
Very Good Partial Response Rate
Time Frame: 2 years
|
Percentage of patients with very good partial response (VGPR) to therapy.
(VGPR is >90% reduction in serum IgM from baseline)
|
2 years
|
Partial Response Rate
Time Frame: 2 years
|
Percentage of patients with partial response (PR) to therapy.
(PR is 50-89% reduction in serum IgM from baseline)
|
2 years
|
Minimal Response Rate
Time Frame: 2 years
|
Percentage of patients with Minor Responses to therapy.
(MR is 25-49% reduction in serum IgM from baseline)
|
2 years
|
Stable Disease Rate
Time Frame: 2 years
|
Percentage of patients with Stable disease to therapy.
(SD is <25% reduction in serum IgM from baseline).
|
2 years
|
Progressive Disease Rate
Time Frame: From first dose through disease progression, up to 2 years from baseline
|
Percentage of patients with who experienced disease progression on study.
PD is >25% increase in serum IgM from baseline with an absolute increase of at least 500 mg/dL, or progression of clinically significant disease related symptoms.
Death from any cause or initiation of a new anti-neoplastic therapy will also be considered a progression event.
An increase of 1 cm in any axis for adenopathy, or 2 cm in the craniocaudal axis of the spleen will be considered evidence of progression of extramedullary disease.
Development of Bing Neel syndrome, or other extramedullary disease manifestations, as well as disease transformation will be considered as progressive events.
|
From first dose through disease progression, up to 2 years from baseline
|
Progression Free Survival
Time Frame: From first dose through disease progression, up to 2 years from baseline
|
The amount of time between starting treatment and experiencing disease progression.
PD is >25% increase in serum IgM from baseline with an absolute increase of at least 500 mg/dL, or progression of clinically significant disease related symptoms.
Death from any cause or initiation of a new anti-neoplastic therapy will also be considered a progression event.
An increase of 1 cm in any axis for adenopathy, or 2 cm in the craniocaudal axis of the spleen will be considered evidence of progression of extramedullary disease.
Development of Bing Neel syndrome, or other extramedullary disease manifestations, as well as disease transformation will be considered as progressive events.
|
From first dose through disease progression, up to 2 years from baseline
|
Time to Next Therapy (TTNT)
Time Frame: From first dose through initiation of new therapy, up to 2 years from baseline
|
The amount of time between starting study treatment and initiating a new therapy
|
From first dose through initiation of new therapy, up to 2 years from baseline
|
Overall Survival
Time Frame: From first dose through death, up to 2 years from baseline
|
The number of participants who are still alive at the end of follow-up.
Participants were observed for up to 2 years after discontinuing study therapy for survival status.
|
From first dose through death, up to 2 years from baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jorge Castillo, MD, Dana-Farber Cancer Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Waldenstrom Macroglobulinemia
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Dasatinib
Other Study ID Numbers
- 19-305
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Waldenstrom Macroglobulinemia
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingWaldenstrom Macroglobulinemia | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedRecurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom MacroglobulinemiaUnited States
-
BeiGeneRecruitingWaldenstrom Macroglobulinemia | Waldenstrom's Macroglobulinemia Recurrent | Waldenstrom's Macroglobulinemia RefractoryUnited States, Australia, China, Spain, United Kingdom
-
Kosin University Gospel HospitalRecruitingWaldenström's MacroglobulinemiaKorea, Republic of
-
BeiGeneCompletedWaldenström's MacroglobulinemiaUnited States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
-
Dana-Farber Cancer InstituteBristol-Myers SquibbActive, not recruitingWaldenstrom's MacroglobulinemiaUnited States
-
Dana-Farber Cancer InstituteJanssen, LPCompletedWaldenström MacroglobulinemiaUnited States
-
Central Hospital, Nancy, FranceCompletedWaldenström MacroglobulinemiaFrance
-
Fondazione Italiana Linfomi ONLUSCompletedWaldenstrom's MacroglobulinemiaItaly
Clinical Trials on Dasatinib
-
Bristol-Myers SquibbCompletedPharmacokinetic Study in Healthy ParticipantsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Completed
-
Hyoung Jin KangNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric
-
National Cancer Institute (NCI)WithdrawnHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)NRG OncologyTerminatedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Recurrent Uterine Corpus CancerUnited States
-
Xspray Pharma ABQPS Bioserve India Pvt LimitedCompleted
-
Peking University Cancer Hospital & InstituteUnknownGastrointestinal Stromal TumorChina
-
Kanto CML Study GroupUnknownMyelogenous Leukemia, Chronic, Chronic PhaseJapan
-
Jonsson Comprehensive Cancer CenterBristol-Myers SquibbCompleted
-
Swiss Group for Clinical Cancer ResearchCompletedGastrointestinal Stromal TumorFrance, Switzerland, Germany, Finland